Robert von Rosen is a partner in the Basel office of Walder Wyss. His practice focuses on domestic and international M&A transactions (mainly private M&A/private equity and venture capital) with a focus on telecommunication, energy and life sciences. In addition, he advises mainly medium-sized and start-up companies and SMEs on questions of corporate governance, compliance, restructuring and all other legal aspects of day-to-day business operations. Robert von Rosen is a board member of several corporations and foundations (e.g. Optiswiss Ltd, Holle baby food Ltd. GRS Wieland Foundation).

After completing an apprenticeship in banking, Robert von Rosen studied at the Albert-Ludwigs-University Freiburg, Germany (law exam 2004, bar exam 2006). During that time, he worked as scientific assistant at the professorship in civil law, industrial property protection and copyright law. Before joining Walder Wyss, Robert von Rosen worked for eight years at a leading Swiss law firm, supplemented by a secondment with the Swiss Financial Market Supervisory Authority FINMA.

Robert von Rosen practices in German and English. He is registered with the Basel bar registry and is also admitted to the bar in Germany.

Axalta Coating Systems Group acquires André Koch AG

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

CONVOTIS stärkt seine Position in der Schweiz durch die neueste Akquisition der acdalis AG, einem anerkannten Spezialisten für Managed Cloud und Infrastruktur Services.

Coopers acquires iET Group

IFLR 1000 Rankings - Walder Wyss as a top-performing law firm ranked

The Best Lawyers Awards 2024

GEODIS acquires ITS - International Transport & Shipping Ltd. and expands its freight forwarding offering in Switzerland

Datacolor acquires matchmycolor

PwC Switzerland acquires Avoras

Skribble AG completes Series A round of funding joins Elvaston

Elvaston sells Magnolia International AG to GENUI

Cawood acquires IES Ltd

proLogistik Holding GmbH acquires XELOG AG

Dr. Wild & Co. AG sold its Pharma business to Verfora AG

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion

Noema Pharma CHF 54m Series A Financing

Synendos Therapeutics CHF 20m Series A Financing

BioVersys CHF 19 mio. Series B Financing Round

Versant Ventures launches Matterhorn Biosciences

ImmunOs Therapeutics AG raises CHF 15m in Series A Financing

Lindsay Goldberg acquires Bilcare Research Group

GrandVision acquires McOptic

Boehringer Ingelheim acquires Amal Therapeutics SA

CHF 12.5 Million financing round in Alentis Therapeutics AG

NNIT acquires Halfmann Goetsch Partner AG

Precision Surfacing Solutions acquires Meyer Burger's wafering business

SHS invests in Swiss life science company evitria AG

Cellestia Biotech AG: CHF 20 million Series A financing round

BC Platforms CHF 10 Mio. B Round

RWS acquires LUZ, Inc.

Spadina House AG acquires SkyVision

Acino divests its patch business to Luye Pharma Group Ltd.

Bayer and CRISPR Therapeutics form Gene Editing Joint Venture

Honeywell acquires Aviaso

Acquisition and Refinancing of Boost Holding Ltd.

Energiedienst Holding AG and TRITEC are pooling their know-how

Avanade to aquire

P&I Personal & Informatik Ltd. acquires business division HR from Soreco Ltd.

SVC-AG für KMU Risikokapital acquires minority stake in Stratpharma AG

Valens Clinics acquire Rheinburg Clinics